Kura Oncology, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $40.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Kura Oncology’s promising developments in the treatment of acute myeloid leukemia (AML). The initiation of the Phase 3 KOMET-017 trial marks a significant advancement for ziftomenib, particularly in the frontline AML setting. This trial is unique as it is the only menin inhibitor program pursuing registrational trials across both intensive and non-intensive chemotherapy regimens, which could potentially address a broad spectrum of AML patients.
Furthermore, the potential approval of ziftomenib as a monotherapy for relapsed/refractory AML by the fourth quarter of 2025 strengthens its therapeutic profile. The drug has demonstrated strong efficacy, simplicity in dosing, compatibility with other treatments, and a favorable safety profile. These factors, combined with the ongoing studies and the upcoming PDUFA date, suggest a robust foundation for ziftomenib’s potential to target multiple AML settings and mutations, making Kura Oncology a compelling investment opportunity.
According to TipRanks, Pantginis is an analyst with an average return of -5.7% and a 39.41% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, Travere Therapeutics, and Cytokinetics.
In another report released on September 18, Barclays also maintained a Buy rating on the stock with a $11.00 price target.